| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
- |
| Employees |
202 |
| Revenues (TTM) (Millions $) |
376 |
| Net Income (TTM) (Millions $) |
3 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Pharming Group N.V. is a Dutch biopharmaceutical company specializing in the development of innovative treatments for rare diseases. The company has its headquarter in Leiden, the Netherlands and operates globally.
Pharming is primarily focused on developing products for the treatment of hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling and inflammation. The company's most significant product is RUCONEST, a recombinant human C1 esterase inhibitor used to treat acute attacks of HAE. RUCONEST is approved for use in Europe and the United States and has been used by thousands of patients worldwide.
Pharming is also developing new products for the treatment of other rare diseases, including Pompe disease, Fabry disease, and phenylketonuria. The company's pipeline also includes products for the treatment of various types of cancer, including Natural Killer T-cell lymphoma and acute myeloid leukemia.
The company has received numerous awards and recognitions for its innovations in the biopharmaceutical industry. Pharming was awarded the Best Performing Biotech in Europe in 2019 and was named one of the top ten most innovative companies in the Netherlands by the Dutch Chamber of Commerce.
In addition to its focus on research and development, Pharming is active in promoting patient awareness and advocacy. The company works closely with patient organizations to improve patient access to treatments and supports various patient education initiatives.
Pharming has a strong financial position, with steady growth in revenue and market capitalization over the past few years. The company is publicly traded on multiple stock exchanges, including Euronext Amsterdam, NASDAQ, and the Swiss SIX Exchange.
Overall, Pharming Group N.V. is a highly respected and innovative biopharmaceutical company that is dedicated to improving the lives of patients with rare diseases through the development of effective and safe treatments.
Company Address: Darwinweg 24 Leiden 2333
Company Phone Number: 5247 400 Stock Exchange / Ticker: NASDAQ PHAR
|
84.64 %